ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2020 - 2021)

ARS Pharmaceuticals' (SPRY) quarterly Amortization of Deferred Charges came in at $1000.0 in Q2 2021, down 80.0% year-on-year from $5000.0 in Q2 2020, and little changed quarter-over-quarter from $1000.0 in Q1 2021.

ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends

ARS Pharmaceuticals has disclosed Amortization of Deferred Charges across 2 years of filings, most recently posting $1000.0 for Q2 2021.

  • Amortization of Deferred Charges for Q2 2021 came in at $1000.0, down 80.0% year-over-year; the trailing twelve-month figure through Dec 2021 was $2000.0 (down 93.55% YoY), and the FY2021 annual result was $2000.0, down 93.55% from the prior year.
  • Amortization of Deferred Charges came in at $1000.0 for Q2 2021 at ARS Pharmaceuticals, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $20000.0 in Q1 2020 to a low of $1000.0 in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 ARS Pharmaceuticals 954.24 Mn 753.27 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2021 1,000.00
Jun 30, 2021 1,000.00
Mar 31, 2021 1,000.00
Mar 31, 2021 1,000.00
Dec 31, 2020 3,000.00
Dec 31, 2020 3,000.00
Sep 30, 2020 3,000.00
Sep 30, 2020 3,000.00
Jun 30, 2020 5,000.00
Jun 30, 2020 5,000.00
Mar 31, 2020 20,000.00
Mar 31, 2020 20,000.00